洛铂联合多西他赛治疗晚期非小细胞肺癌的疗效观察  

Observation on Efficacy of Lobaplatin Combined with Docetaxel in Treatment of Advanced Non Small Cell Lung Cancer

作　　者：杨俊红[1] 李志英[1] YANG Junhong;LI Zhiying(Dept.of Internal Medicine,Anyang Cancer Hospital,Henan Anyang 455000,China)

机构地区：[1]安阳肿瘤医院内科,河南安阳455000

出　　处：《中国医院用药评价与分析》2019年第1期45-47,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨洛铂联合多西他赛治疗晚期非小细胞肺癌的临床疗效。方法:选取2016年2月至2018年2月安阳肿瘤医院收治的晚期非小细胞肺癌患者120例,按照随机数字表法分为对照组与观察组,每组60例。对照组患者给予顺铂联合多西他赛治疗,观察组患者给予洛铂联合多西他赛治疗。比较两组患者的临床疗效、不良反应发生情况、中位生存期及疾病无进展生存期的差异。结果:治疗2个周期后,观察组、对照组患者总有效率分别为50.00%(30/60)、33.33%(20/60),差异无统计学意义(P>0.05);观察组患者胃肠道反应、便秘的发生率明显低于对照组,血小板减少症发生率明显高于对照组,差异有统计学意义(P<0.05);观察组患者中位生存期为24.0个月,明显长于对照组的16.0个月,差异有统计学意义(P<0.05);两组患者疾病无进展生存期的差异无统计学意义(P>0.05)。结论:洛铂联合多西他赛用于晚期非小细胞肺癌患者,虽不能明显提高疗效,但能够显著降低患者的胃肠道反应和便秘等不良反应的发生率,提高患者的舒适度。OBJECTIVE:To probe into the clinical efficacy of lobaplatin combined with docetaxel in treatment of advanced non small cell lung cancer(NSCLC).METHODS:120 patients with advanced NSCLC admitted into Anyang Cancer Hospital from Feb.2016 to Feb.2018 were selected and divided into control group and observation group via random number table,with 60 cases in each.The control group was given cis-platinum combined with docetaxel,while the observation group was given lobaplatin combined with docetaxel.Differences in clinical efficacy,incidences of adverse drug reactions,median survival time and progression free survival between two groups were compared.RESULTS:After 2 treatment courses,the total effective rates of observation group and control group were repsectively 50.00%(30/60)and 33.33%(20/60),the difference had no statistical significance(P >0.05);the incidences of gastrointestinal reaction and constipation of observation group were significantly lower than those of the control group,while the depletion rate of blood platelet of observation group was significantly higher,with statistically significant differences(P<0.05);the median survival time of observation group was 24.0 months,which was significantly longer than that of the control group(16.0 months),with statistically significant difference(P<0.05);there was no statistical significance in difference in progression free survival between two groups(P >0.05).CONCLUSIONS:Lobaplatin combined with docetaxel is not effective in improving patients with advanced NSCLC,while it can significantly reduce the incidence of adverse drug reactions such as gastrointestinal reactions and constipation,and improve patient comfort.

关 键 词：洛铂 多西他赛 非小细胞肺癌 疗效 

分 类 号：R979.1[医药卫生—药品]